{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:19:38Z","timestamp":1785161978213,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013223","name":"Chongqing Research Program of Basic Research and Frontier Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Parkinson's disease (PD) is one of the most common chronic, progressive, and neurodegenerative diseases characterized clinically by resting tremor, bradykinesia, rigidity, and postural instability. As this disease is usually detected in the later stages, the cure is often delayed, ultimately leading to disability due to the lack of early diagnostic techniques. Therefore, it is of great importance to identify reliable biomarkers with high sensitivity and specificity for the early diagnosis of PD. In this study, we aimed to investigate whether serum expressions of mature brain-derived neurotrophic factor (mBDNF) and proBDNF can serve as biomarkers for the diagnosis of PD at early stage. One hundred and fifty-six patients with limb tremor and\/or bradykinesia meeting the inclusion criteria were assigned to either ex-PD group (PD cases) or ex-NPD group (non-PD cases) and then reassigned to either po-PD group (with PD) or po-NPD group (without PD) at 1-year follow-up based on the results of the rediagnoses as performed in accordance with MDS Parkinson's diagnostic criteria. To improve early diagnostic accuracy, grouping (PD group and non-PD group) at initial visit and follow-up was performed differently and independently. Serum mBDNF and proBDNF levels were measured by enzyme-linked immunosorbent assays. The results demonstrated that serum levels of mBDNF and mBDNF\/proBDNF were significantly lower in the ex-PD group (19.73 \u00b1 7.31 and 0.09 \u00b1 0.05 ng\/ml) as compared with the ex-NPD group (23.47 \u00b1 8.21 and 0.15 \u00b1 0.12 ng\/ml) (<jats:italic>p<\/jats:italic> &amp;lt; 0.01 for both) and in the po-PD group (19.24 \u00b1 7.20 and 0.09 \u00b1 0.05 ng\/ml) as compared with the po-NPD group (25.05 \u00b1 7.67 and 0.16 \u00b1 0.14 ng\/ml) (<jats:italic>p<\/jats:italic> &amp;lt; 0.01 for both). However, a significantly higher serum level of proBDNF was noted in the ex-PD group (235.49 \u00b1 60.75 ng\/ml) as compared with the ex-NPD group (191.75 \u00b1 66.12 ng\/ml) (<jats:italic>p<\/jats:italic> &amp;lt; 0.01) and in the po-PD group (235.56 \u00b1 60.80 ng\/ml) as compared with the po-NPD group (188.42 \u00b1 65.08 ng\/ml) (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). In conclusion, mBDNF\/proBDNF can be used as biomarkers for early stage Parkinson's disease; in addition, mBDNF plus proBDNF has better diagnostic value than mBDNF alone in the diagnosis of PD.<\/jats:p>","DOI":"10.3389\/fneur.2021.680765","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T05:43:02Z","timestamp":1628660582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Xu","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging."},{"key":"B2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA."},{"key":"B3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/RLU.0000000000002148","article-title":"Clinical, dopaminergic, and metabolic correlations in parkinson disease: a dual-tracer PET study","volume":"43","author":"Liu","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.expneurol.2004.11.030","article-title":"Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons","volume":"192","author":"Porritt","year":"2005","journal-title":"Exp Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature19766","article-title":"Autocrine BDNF-TrkB signalling within a single dendritic spine","volume":"538","author":"Harward","year":"2016","journal-title":"Nature."},{"key":"B6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrd3366","article-title":"Potential therapeutic uses of BDNF in neurological and psychiatric disorders","volume":"10","author":"Nagahara","year":"2011","journal-title":"Nat Rev Drug Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1006\/exnr.2000.7483","article-title":"Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra","volume":"166","author":"Howells","year":"2000","journal-title":"Exp Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0304-3940(99)00463-2","article-title":"Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease","volume":"270","author":"Mogi","year":"1999","journal-title":"Neurosci Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/00001756-199902250-00021","article-title":"Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra","volume":"10","author":"Parain","year":"1999","journal-title":"Neuroreport."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.expneurol.2004.08.018","article-title":"Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism","volume":"191","author":"Collier","year":"2005","journal-title":"Exp Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10571-010-9523-y","article-title":"Overexpression of alpha-synuclein down-regulates BDNF expression","volume":"30","author":"Yuan","year":"2010","journal-title":"Cell Mol Neurobiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10773","DOI":"10.1073\/pnas.1713969114","article-title":"TrkB neurotrophic activities are blocked by alpha-synuclein, triggering dopaminergic cell death in Parkinson's disease","volume":"114","author":"Kang","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/syn.10027","article-title":"Striatal dopamine output is compromised within +\/- BDNF mice","volume":"43","author":"Dluzen","year":"2002","journal-title":"Synapse."},{"key":"B14","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stemcr.2015.09.008","article-title":"Neural stem cells rescue cognitive and motor dysfunction in a transgenic model of dementia with lewy bodies through a BDNF-dependent mechanism","volume":"5","author":"Goldberg","year":"2015","journal-title":"Stem Cell Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0006-8993(95)00596-I","article-title":"Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease","volume":"691","author":"Yoshimoto","year":"1995","journal-title":"Brain Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.33549\/physiolres.932743","article-title":"Protection of dopamine neurons by vibration training and up-regulation of brain-derived neurotrophic factor in a MPTP mouse model of Parkinson's disease","volume":"63","author":"Zhao","year":"2014","journal-title":"Physiol Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.2174\/0929867325666180313101536","article-title":"Neurotrophic factors in Parkinson's Disease: what have we learned from pre-clinical and clinical studies?","volume":"25","author":"Ferreira","year":"2018","journal-title":"Curr Med Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jocn.2008.03.010","article-title":"Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease","volume":"16","author":"Salehi","year":"2009","journal-title":"J Clin Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00415-009-5357-2","article-title":"Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease","volume":"257","author":"Scalzo","year":"2010","journal-title":"J Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.brainres.2018.10.006","article-title":"Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis","volume":"1704","author":"Rahmani","year":"2019","journal-title":"Brain Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0014-5793(92)81430-T","article-title":"Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum","volume":"313","author":"Okazawa","year":"1992","journal-title":"FEBS Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737175.2016.1179582","article-title":"Exercise-induced neuroprotective effects on neurodegenerative diseases: the key role of trophic factors","volume":"16","author":"Campos","year":"2016","journal-title":"Expert Rev Neurother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.neurobiolaging.2012.04.012","article-title":"Impairment of the septal cholinergic neurons in MPTP-treated A30P alpha-synuclein mice","volume":"34","author":"Szego","year":"2013","journal-title":"Neurobiol Aging."},{"key":"B24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.neurobiolaging.2010.11.010","article-title":"Striatal dopamine transporter binding correlates with serum BDNF levels in patients with striatal dopaminergic neurodegeneration","volume":"33","author":"Ziebell","year":"2012","journal-title":"Neurobiol Aging."},{"key":"B25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jns.2016.01.032","article-title":"Relationship of circulatory BDNF with cognitive deficits in people with Parkinson's disease","volume":"362","author":"Khalil","year":"2016","journal-title":"J Neurol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0304-3940(02)00529-3","article-title":"Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets","volume":"328","author":"Karege","year":"2002","journal-title":"Neurosci Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrn3505","article-title":"BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases","volume":"14","author":"Lu","year":"2013","journal-title":"Nat Rev Neurosci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat Rev Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington's disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog Neurobiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1177\/0300060517748843","article-title":"Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor","volume":"46","author":"Huang","year":"2018","journal-title":"J Int Med Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"901082","DOI":"10.1155\/2013\/901082","article-title":"Serum brain-derived neurotrophic factor levels in different neurological diseases","volume":"2013","author":"Ventriglia","year":"2013","journal-title":"Biomed Res Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00726-005-0162-4","article-title":"Peculiarities of L: -DOPA treatment of Parkinson's disease","volume":"28","author":"Kostrzewa","year":"2005","journal-title":"Amino Acids."},{"key":"B34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nm875","article-title":"Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function","volume":"9","author":"Bezard","year":"2003","journal-title":"Nat Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.jocn.2011.03.015","article-title":"Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson's disease in a Greek population","volume":"18","author":"Karakasis","year":"2011","journal-title":"J Clin Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.680765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T05:43:05Z","timestamp":1628660585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.680765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":35,"alternative-id":["10.3389\/fneur.2021.680765"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.680765","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"article-number":"680765"}}